search
Back to results

A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest

Primary Purpose

Thymic Malignancies, Pleural Metastases

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Intensity-Modulated Pleural Radiation Therapy (IMPRINT)
Sponsored by
Memorial Sloan Kettering Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Thymic Malignancies focused on measuring Intensity-Modulated Pleural Radiation Therapy (IMPRINT), 22-098

Eligibility Criteria

18 Years - 79 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Provide written informed consent to participate on the study
  • Patients must have a pathologically confirmed diagnosis of thymic malignancy. Thymic carcinoma is allowed.
  • Patients must have radiologic or pathologic evidence of pleural metastases. Patients may have de novo stage IVA or recurrent disease in the pleura. Gross disease in the fissure is allowed if resected.
  • No evidence of extrathoracic metastatic disease or contralateral pleural/pericardial disease.
  • Patient age ≥ 18 years but ≤ 80 years at the time of consent
  • Karnofsky performance status ≥ 80%
  • Preoperative or Postoperative Pulmonary Function Tests: DLCO > 40% predicted (corrected for Hgb) and FEV1 ≥ 35% (corrected for Hgb)
  • Glomerular filtration rate (GFR): ≥50 mL/min/1.73 m2 (must be calculated using estimated creatinine clearance (CrCl) by the Cockcroft-Gault (C-G) equation (Nephron 1976;16:31-41): CrCl (mL/min) = [140 - age (years)] x weight (kg) [x 0.85 for female patients] 72 x serum creatinine (mg / dL) ° In cases of concern about decreased renal function and potential high radiation dose to the kidneys, an optional nuclear medicine kidney function scan may be performed prior to radiation therapy to determine the functional contribution of each kidney.

Exclusion Criteria:

  • Continuous oxygen use
  • History of myasthenia gravis as these patients may be at increased risk for pneumonitis
  • Prior nephrectomy on the contralateral side of the pleural metastases
  • Prior thoracic radiation therapy preventing hemithoracic pleural IMRT. Prior thymic bed radiation is allowed. Prior pleural SBRT is allowed.
  • Patients undergoing extrapleural pneumonectomy. Other surgical resection approaches of the pleural nodules (ex: P/D, debulking/metastasectomy) are allowed. Surgical resection of the primary thymic tumor is allowed.
  • Acute congestive heart failure requiring hospitalization within the past 30 days.
  • COPD requiring chronic oral steroid therapy of > 10 mg prednisone daily or equivalent at the time of registration. Inhaled corticosteroids are allowed
  • Unstable angina requiring hospitalization and/or transmural myocardial infarction within the last 3 months
  • History of interstitial lung disease
  • Pregnant or lactating women
  • Men or women not using effective contraception

Sites / Locations

  • Memorial Sloan Kettering Basking Ridge (Limited protocol activities)Recruiting
  • Memorial Sloan Kettering Monmouth (Limited protocol activities)Recruiting
  • Memorial Sloan Kettering Bergen (Limited protocol activities)Recruiting
  • Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities)Recruiting
  • Memorial Sloan Kettering Westchester (Limited protocol activities)Recruiting
  • Memorial Sloan Kettering Cancer CenterRecruiting
  • Memorial Sloan Kettering Nassau (Limited protocol activities)Recruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT)

Arm Description

Radiation will be administered over approximately 6 weeks to 50.4 Gy in 28 fractions with an optional SIB to gross residual disease.

Outcomes

Primary Outcome Measures

assess the rate of radiation pneumonitis
as indicated by the rate of grade 3 or higher radiation pneumonitis defined by the NCI Common Terminology Criteria (CTC) version 5.0.

Secondary Outcome Measures

progression-free survival (PFS)
PFS events will include death and/or progression of thymic malignancy due to local-regional or distant recurrence/progression. PFS will be calculated from the start of radiation treatment and will be estimated by the Kaplan-Meier method.

Full Information

First Posted
April 26, 2022
Last Updated
May 2, 2023
Sponsor
Memorial Sloan Kettering Cancer Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05354570
Brief Title
A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest
Official Title
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Patients With Pleural Metastases From Thymic Malignancies
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 26, 2022 (Actual)
Primary Completion Date
April 2026 (Anticipated)
Study Completion Date
April 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Memorial Sloan Kettering Cancer Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes

5. Study Description

Brief Summary
The researchers are doing this study to find out whether hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) is a safe treatment that causes few or mild side effects in people with pleural metastases from thymic malignancies. The researchers will also look at whether hemithoracic IMPRINT is effective against participants' cancer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thymic Malignancies, Pleural Metastases
Keywords
Intensity-Modulated Pleural Radiation Therapy (IMPRINT), 22-098

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Model Description
This is a single-arm Phase II single institution trial.
Masking
None (Open Label)
Allocation
N/A
Enrollment
36 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT)
Arm Type
Experimental
Arm Description
Radiation will be administered over approximately 6 weeks to 50.4 Gy in 28 fractions with an optional SIB to gross residual disease.
Intervention Type
Radiation
Intervention Name(s)
Intensity-Modulated Pleural Radiation Therapy (IMPRINT)
Intervention Description
Radiation therapy will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions, including an optional dose-painting SIB to gross residual disease up to 60 Gy while respecting normal tissue constraints.
Primary Outcome Measure Information:
Title
assess the rate of radiation pneumonitis
Description
as indicated by the rate of grade 3 or higher radiation pneumonitis defined by the NCI Common Terminology Criteria (CTC) version 5.0.
Time Frame
2 years
Secondary Outcome Measure Information:
Title
progression-free survival (PFS)
Description
PFS events will include death and/or progression of thymic malignancy due to local-regional or distant recurrence/progression. PFS will be calculated from the start of radiation treatment and will be estimated by the Kaplan-Meier method.
Time Frame
12 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Provide written informed consent to participate on the study Patients must have a pathologically confirmed diagnosis of thymic malignancy. Thymic carcinoma is allowed. Patients must have radiologic or pathologic evidence of pleural metastases. Patients may have de novo stage IVA or recurrent disease in the pleura. Gross disease in the fissure is allowed if resected. No evidence of extrathoracic metastatic disease or contralateral pleural/pericardial disease. Patient age ≥ 18 years but ≤ 80 years at the time of consent Karnofsky performance status ≥ 80% Preoperative or Postoperative Pulmonary Function Tests: DLCO > 40% predicted (corrected for Hgb) and FEV1 ≥ 35% (corrected for Hgb) Glomerular filtration rate (GFR): ≥50 mL/min/1.73 m2 (must be calculated using estimated creatinine clearance (CrCl) by the Cockcroft-Gault (C-G) equation (Nephron 1976;16:31-41): CrCl (mL/min) = [140 - age (years)] x weight (kg) [x 0.85 for female patients] 72 x serum creatinine (mg / dL) ° In cases of concern about decreased renal function and potential high radiation dose to the kidneys, an optional nuclear medicine kidney function scan may be performed prior to radiation therapy to determine the functional contribution of each kidney. Exclusion Criteria: Continuous oxygen use History of myasthenia gravis as these patients may be at increased risk for pneumonitis Prior nephrectomy on the contralateral side of the pleural metastases Prior thoracic radiation therapy preventing hemithoracic pleural IMRT. Prior thymic bed radiation is allowed. Prior pleural SBRT is allowed. Patients undergoing extrapleural pneumonectomy. Other surgical resection approaches of the pleural nodules (ex: P/D, debulking/metastasectomy) are allowed. Surgical resection of the primary thymic tumor is allowed. Acute congestive heart failure requiring hospitalization within the past 30 days. COPD requiring chronic oral steroid therapy of > 10 mg prednisone daily or equivalent at the time of registration. Inhaled corticosteroids are allowed Unstable angina requiring hospitalization and/or transmural myocardial infarction within the last 3 months History of interstitial lung disease Pregnant or lactating women Men or women not using effective contraception
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Annemarie Shepherd, MD
Phone
908-542-3430
Email
shephera@mskcc.org
First Name & Middle Initial & Last Name or Official Title & Degree
Andreas Rimner, MD
Phone
646-608-2449
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Annemarie Shepherd, MD
Organizational Affiliation
Memorial Sloan Kettering Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Memorial Sloan Kettering Basking Ridge (Limited protocol activities)
City
Basking Ridge
State/Province
New Jersey
ZIP/Postal Code
07920
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annemarie Shepherd, MD
Phone
908-542-3430
Facility Name
Memorial Sloan Kettering Monmouth (Limited protocol activities)
City
Middletown
State/Province
New Jersey
ZIP/Postal Code
07748
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annemarie Shepherd, MD
Phone
908-542-3430
Facility Name
Memorial Sloan Kettering Bergen (Limited protocol activities)
City
Montvale
State/Province
New Jersey
ZIP/Postal Code
07645
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annemarie Shepherd, MD
Phone
908-542-3430
Facility Name
Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities)
City
Commack
State/Province
New York
ZIP/Postal Code
11725
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annemarie Shepherd, MD
Phone
908-542-3430
Facility Name
Memorial Sloan Kettering Westchester (Limited protocol activities)
City
Harrison
State/Province
New York
ZIP/Postal Code
10604
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annemarie Shepherd, MD
Phone
908-542-3430
Facility Name
Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annemarie Shepherd, MD
Phone
908-542-3430
Facility Name
Memorial Sloan Kettering Nassau (Limited protocol activities)
City
Rockville Centre
State/Province
New York
ZIP/Postal Code
11553
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annemarie Shepherd, MD
Phone
908-542-3430

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Links:
URL
http://www.mskcc.org/mskcc/html/44.cfm
Description
Memorial Sloan Kettering Cancer Center

Learn more about this trial

A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest

We'll reach out to this number within 24 hrs